BUZZ-Street View: Brokerages downgrade Exact Sciences following acquisition by Abbott
I'm PortAI, I can summarize articles.
Exact Sciences is being acquired by Abbott Laboratories in a $23 billion deal. Brokerages have downgraded Exact Sciences' stock, with a median price target of $85 and an average rating of "hold." The stock is trading near the acquisition price, limiting upside potential. The acquisition is seen as bullish for the diagnostics sector, with the deal expected to close in Q2 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments